Pandora Report: 6.14.2019

It’s nearly July, have you signed up for the Summer Workshop on Pandemics, Bioterrorism, and Global Health Security, to get your early registration discount? Also – as you enjoy the summer weather, practice bat safety, as the CDC has warned that they post the biggest rabies threat in the United States.

How World War II Spurred Vaccine Innovation
Dr. Kendall Hoyt discusses the link between war and disease, and how WWII helped bring forth a renaissance of vaccine development. Did we mention she’ll be speaking at our summer workshop next month? “As the Second World War raged in Europe, the U.S. military recognized that infectious disease was as formidable an enemy as any other they would meet on the battlefield. So they forged a new partnership with industry and academia to develop vaccines for the troops. Vaccines were attractive to the military for the simple reason that they reduced the overall number of sick days for troops more effectively than most therapeutic measures. This partnership generated unprecedented levels of innovation that lasted long after the war was over. As industry and academia began to work with the government in new ways to develop vaccines, they discovered that many of the key barriers to progress were not scientific but organizational.”

Ebola Outbreak – Expanding into Uganda 
By June 12th, the Ugandan Ministry of Health had confirmed three cases of Ebola along the DRC border. In many ways, this was the scenario public health officials had been expecting and fearing. “For 10 months, Uganda has closely monitored its porous border with the DRC for crossover cases, yet, despite numerous alerts, no cases have been detected until now. ‘In preparation for a possible imported case during the current outbreak in DRC, Uganda has vaccinated nearly 4,700 health workers in 165 health facilities (including in the facility where the child is being cared for); disease monitoring has been intensified; and health workers trained on recognizing symptoms of the disease. Ebola Treatment Units are in place,’ the WHO regional office for Africa said in a news release.” Given the growth of the outbreak and now cases in Uganda, many are wondering why the WHO has not declared this outbreak a PHEIC (public health emergency of international concern). This may change though, as the WHO Director-General Dr. Tedros has convened an Emergency Committee under the International Health Regulations for Friday (FYI, this is the third time the Emergency committee has met to discuss the outbreak and classification as a PHEIC). Concerns for the delay in declaring PHEIC have been present for months – “The legal criteria for a PHEIC have been met. The International Health Regulations (2005) (IHR) empower the WHO Director-General to declare a PHEIC. A PHEIC is an extraordinary event with public health risk to other countries that requires a coordinated international response. IHR criteria include public health impact, novelty and scale, and movement of persons. The WHO Director-General must also consider health risks, potential international spread, and EC guidance, among other factors.”

Fighting Global Pandemics By Starting One
In the latest video installment from the Bulletin of the Atomic Scientists’s Say What? series, the hot topic of gain-of-function research is being discussed. “Researchers say making new strains of the H5N1 flu virus in a secure lab can help them see what might happen naturally in the real world. Sounds logical, but many scientists oppose it because the facts show most biosafety labs aren’t really secure at all, and experts say the risks of a mutated virus escaping outweigh whatever public health benefit comes from creating them. But now the US government is funding these same labs again to artificially enhance potentially pandemic pathogens. In this installment of the Bulletin’s video series that provides a sharp view of fuzzy policy, Johns Hopkins University computational biologist Steven Salzberg explains why arguments by researchers in favor of risky viral research aren’t persuasive.”

Burden of Disease Exposures- Reasons to Invest in Hospital Response
GMU biodefense doctoral student and infection preventionist Saskia Popescu discusses the impact that communicable disease exposures have on hospitals. “The time spent responding to an exposure means less time for patient care and infection prevention, but can also result in health care workers having to stay home if they’re exposed and immuno-naïve. A new survey sought to understand the impact for infection preventionist and staff nurses when an exposure to a communicable disease occurs. Investigators wrote in the American Journal of Infection Control (AJIC) regarding this very issue and surveyed staff nurses in a New York hospital network and infection preventionists at the 2018 Association for Professionals in Infection Control and Epidemiology annual conference, as well as members of the Association for Professionals in Infection Control and Epidemiology chapters.  A total of 150 nurses and 228 infection preventionists responded with some insight into just how time-consuming these exposures are. Data regarding workload increase for each exposure was captured in 2 questions asking participants to rank the overall increase in daily workload for each of these exposures (0-3 scale, with 0 meaning not applicable and 3 meaning a dramatic increase in workload of more than 60 minutes), and to explain the 3 most time-consuming activities for outbreak and exposure activities. Infection preventionists reported the most time-consuming outbreaks/exposures resulted from mumps/measles, tuberculosis, gastrointestinal viruses, and multidrug-resistant organisms. For an exposure to Clostridioides difficile, lice or scabies, and influenza, there was a more than 60-minute workload increase for nurses.”

There’s Limited Time To Make America Safer From Epidemics
Dr. Tom Frieden and Margaret Hamburg shine a light on a harsh truth – we’re on tight window if we want to avoid a pandemic. “In one week, the World Bank will decide how to allocate more than $50 billion in development funding to lower income countries. The World Bank should dedicate some of its International Development Association (IDA) funds – say, 5 percent, or about $1 billion per year over three years – to help countries become better prepared for infectious disease outbreaks.” “Disease outbreaks can wipe out years of investments and severely damage development. Economic losses can dwarf the cost of response – the World Bank estimates that SARS cost the global economy $54 billion in little over half a year and that a severe flu pandemic could cost more than $3 trillion, nearly five percent of global GDP. Because of its global reach, the World Bank is in the best position to take the lead on this critical effort, but the United States delegation has one week to make sure it does so at its annual meeting on June 17. The total needed to close preparedness gaps is estimated at about $4.5 billion annually, less than $1 per person per year. An additional $1 billion infusion each year for the next three years will provide a tremendous jump start – and is a bargain the United States cannot afford to miss.”

Russian Biologist Plans for More CRISPR Babies
Just went you thought the CRISPR baby drama was over (or at least being managed)…. “A Russian scientist says he is planning to produce gene-edited babies, an act that would make him only the second person known to have done this. It would also fly in the face of the scientific consensus that such experiments should be banned until an international ethical framework has agreed on the circumstances and safety measures that would justify them. Molecular biologist Denis Rebrikov has told Nature he is considering implanting gene-edited embryos into women, possibly before the end of the year if he can get approval by then. Chinese scientist He Jiankui prompted an international outcry when he announced last Novemberthat he had made the world’s first gene-edited babies — twin girls. The experiment will target the same gene, called CCR5, that He did, but Rebrikov claims his technique will offer greater benefits, pose fewer risks and be more ethically justifiable and acceptable to the public. Rebrikov plans to disable the gene, which encodes a protein that allows HIV to enter cells, in embryos that will be implanted into HIV-positive mothers, reducing the risk of them passing on the virus to the baby in utero. By contrast, He modified the gene in embryos created from fathers with HIV, which many geneticists said provided little clinical benefit because the risk of a father passing on HIV to his children is minimal.”

Stories You May Have Missed:

  • Microbial House Designs– “There’s a little mischievousness about bringing all these things and making them visible,” said Mr. Pallrand’s wife, Rachel Mayeri, who based the tile designs on electron microscopy images. “These things we tend to think of as being kind of ugly and want to hide — mold spores and mildew growing in our bathtub, and bacterial colonies that are on all the surfaces of your house — they’re all noncharismatic animals, but they’re really crucial to our lives.”

 

Rebuilding Health Security in the Wake of Ebola

by Stephen Taylor – Schar School of Policy and Government, George Mason University

In late 2013 and early 2014, the West African nation of Guinea was caught unprepared when Ebola cases began spreading in its southeastern districts.  The outbreak rapidly spread to the neighboring countries of Sierra Leone and Liberia.  Lacking the public health capabilities of tracing and isolating Ebola cases and lacking the medical capacity to safely treat Ebola patients, all three countries were quickly overwhelmed as the outbreak grew to pandemic proportions. The pandemic spread to urban centers and then to seven other countries around the world.  In Guinea, Sierra Leone, and Liberia, the pandemic spanned three years and cost over 6 billion USD to bring under control.  Over 28,000 West Africans contracted Ebola virus disease and over 11,000 died.  10% of GDP disappeared in Guinea, Liberia, and Sierra Leone due to lost workforce and productivity.  This further resulted in lowered investment and a loss in private sector growth. Continue reading “Rebuilding Health Security in the Wake of Ebola”

Pandora Report: 5.18.2018

 Ebola Outbreak Update
As the DRC continues work on containing an outbreak of Ebola, the question of response measures and vaccine deployment has come up, especially in light of the recent confirmation of a third case in Wangata, a different health zone. The WHO is calling the confirmation of a patient in a metropolitan area, a “game changer” and has initiated emergency meetings. The recent outbreak data now reports a total of 44 cases, 3 of which are confirmed, 20 probable, and 21 suspected. “‘This is not a health issue alone but a crisis that has negative impact on the socio-economic and political situation of the country and the region at large,’ said Lazare Sebitereko Rukundwa. Rukundwa, is the founder of the Eben-Ezer University of Minembwe in Congo, a Hubert Humphrey Fellow and a visiting scholar at George Mason University’s Schar School of Policy and Government”. In response to these cases, the vaccine (VSV-EBOV) has been deployed to the DRC as of May 16th. 4,000 units of it will be used to help stop the outbreak. “DRC Health Minister Oly Ilunga, MD also tweeted that the vaccines will be kept in special vaccine cold rooms in Kinshasa until they’re ready to be shipped to Mbandaka and Bikoro in the coming days. The Merck-produced unlicensed vaccine will be used to squelch an Ebola virus outbreak currently ongoing in three health zones of the DRC. Health officials will use a ring vaccination strategy, giving the vaccine to close contacts of patients first.”

GMU Workshop on Global Health Security – Don’t Miss Out!
Speaking of an Ebola vaccine…did you know that that Dr. Jens Kuhn (but seriously, he has an MD, PhD, PhD, and MS…so he’s as close to Bruce Banner as you’ll get) will be one of our speakers at the summer workshop? Dr. Kuhn is “a Lead Virologist in the Division of Clinical Research at the National Institutes of Health/National Institute of Allegery and Infectious Diseases Integrated Research Facility at Fort Detrick. Dr. Kuhn specializes in highly virulent viral human and animal pathogens”, specifically filoviruses. “Dr. Kuhn was the first western scientist with permission to work in a former Soviet biological warfare facility, SRCVB ‘Vektor’ in Siberia, Russia, within the US Department of Defense’s Cooperative Threat Reduction (CTR) Program” – which means he’s not only a wealth of knowledge, but has some pretty amazing stories to tell. Don’t miss the chance to learn from and chat with experts like Dr. Kuhn at our workshop in July!

Rhodesia’s Chem-Bio Warfare History
Have you gotten the dirt on the Rhodesian chemical and biological warfare program? If you’re looking for a summer read to boost your knowledge on it, GMU Biodefense PhD alum Glenn Cross’s new book, Dirty War: Rhodesia and Chemical Biological Warfare 1975-1980, is just for you. “Glenn Cross’s Dirty War: Rhodesia and Chemical Biological Warfare 1975–1980 is a welcome addition to the small, but growing scholarly literature on the history of chemical and biological warfare. In 1965, the minority white community in the British territory of Rhodesia (officially Southern Rhodesia) rejected demands that it transfer political power to the majority black population. By the mid-1970s, white Rhodesians found it increasingly difficult to counter the growing power of native African nationalists fighting the government. As with many insurgencies, the guerrillas lacked the resources to defeat government security forces in direct combat, but Rhodesian forces were stretched too thin to suppress the insurgents, especially once they had established base camps in neighboring countries. Amidst the conflict, Rhodesian military and intelligence services employed what would now be considered chemical and biological agents against the guerillas with unknown results.”

 Dangers of the Rising DIY Biohacking
It’s likely not the first time you’ve heard about growing concerns regarding the rising popularity of do-it-yourself (DIY) gene editing. From the horsepox de novo synthesis to public stunts at conventions where biohackers injected themselves with HIV treatment, it’s becoming difficult to ignore why these actions are dangerous. The concern regarding the DIY gene editing community is that there are very little restrictions or regulations surrounding what they can or can’t do in a homemade lab. Sure, you can’t go buy Ebola online, but you can start stitching together horsepox, which is pretty scary. “The study’s publication in the journal PLOS One included an in-depth description of the methods used and — most alarming to Gregory D. Koblentz, the director of the biodefense graduate program at George Mason University — a series of new tips and tricks for bypassing roadblocks. ‘Sure, we’ve known this could be possible,’ Dr. Koblentz said. ‘We also knew North Korea could someday build a thermonuclear weapon, but we’re still horrified when they actually do it’.” NYTimes reporter Emily Baumgaertner points to several DIY biohackers who show an unsettling willingness to inject themselves with things they’ve made in their garage labs and that there are fundamentally large gaps in any kind of regulatory system. It’s important to remember that the stop-gap measures in place, imperfect as they are, are for academic researchers, and don’t pertain to those DIY’ers doing it at home. “Authorities in the United States have been hesitant to undertake actions that could squelch innovation or impinge on intellectual property. The laws that cover biotechnology have not been significantly updated in decades, forcing regulators to rely on outdated frameworks to govern new technologies. The cobbled-together regulatory system, with multiple agencies overseeing various types of research, has left gaps that will only widen as the technologies advance. Academic researchers undergo strict scrutiny when they seek federal funding for ‘dual-use research of concern’: experiments that, in theory, could be used for good or ill. But more than half of the nation’s scientific research and development is funded by nongovernmental sources.” As Baumgaertner notes, there are, of course, those in the DIY community who want to ensure biosecurity/biosafety and are just experimenting however, even biohacker celebrity Josiah Zayner has admitted an accident could happen, which would lead to negative outcomes. Whether you’re at home with your mail-order CRISPR kit or you’re working on policies to implement regulations on the biotech industry, we can all admit that the potential for nefarious actors or laboratory accidents is one that warrants safety measures and a hardcore cultural evaluation within the DIY biohacking community. Check out the latest BBC Radio5Live with Rhod Sharp, in which Dr. Koblentz discusses genome editing, biodefense, CRISPR, and biosecurity issues

GMU Biodefense May Graduates and Awards
Congrats to our graduating GMU Bidoefense graduate students – we’re so proud of your hardwork and are excited to see what kind of amazing biodefense work you’ll do in the future! Congrats to two new Biodefense PhDs – Christopher K. Brown (Protecting Critical U.S. Workers from Occupational Exposure to Emerging Infectious Diseases: Toward A Universal Personal Protective Equipment Selection Matrix for Early Outbreak Response) and Jomana Musmar (The Path to PAHPRA: The Evolution of Pediatric Biodefense Legislation and Medical Countermeasure Development). We’re also excited to announce the following Biodefense MS graduates – Zamawang Almemar, Mariam Awad, Laramie Bradford, Michael Conway, Alexander Dowsett, Sarah Doyle, Stephanie Ellis, Haziq Ghani, Zachary Goble, Stephanie Kiesel, Alexander Rowe, Stephanie Smith, and Alexandra Williams. We’d also like to congratulate three of our biodefense graduate students for their student achievements – Stephanie Smith (Outstanding Biodefense Student), Saskia Popescu (Frances Harbour Award- Biodefense Community Leadership), and Christopher Brown (Outstanding Doctoral Student in Biodefense).

Broad-Spectrum Antibiotic Use in Sub-Saharan Africa: Risk Versus Reward
GMU Biodefense PhD student Saskia Popescu evaluated a recent study that analyzed childhood mortality following a widespread distribution of Azithromycin. Popescu not only looks to the experiment and long-term implications of prophylactic antibiotic use, but she also interviewed the PI of the study. “What this study ultimately shows is the considerable impact that mass distribution of a broad-spectrum antibiotic can have against childhood mortality in Sub-Saharan Africa. Following the publication of the study, however, many have flagged the moral dilemma that follows such results. Although the authors make note of the need for policy implementation for future practices and the potential for antimicrobial resistance, the study has nonetheless posed unique ethical questions. The benefits of mass distribution were supported by their research; however, what sort of long-term costs will such communities pay?”

Restoring Restraint: Enforcing Accountability for Users of Chemical Weapons – Event
Don’t miss out on this panel discussion hosted by the Center for Strategic & International Studies on June 19, 2018 from 9:30-11:30am. The keynote address will be given by H.E. Mr Ahmet Üzümcü, Director-General of the Organization for the Prohibition of Chemical Weapons. “In 2012 a 20-year moratorium on state employment of chemical weapons use was broken. Since then there have been more than 200 uses – against civilians, military targets, and political enemies. These attacks have broken norms against the use of weapons of mass destruction and create a gap in the nonproliferation fabric – despite the robust international architecture of laws, treaties, agreements, and norms designed to restrain the proliferation and use of these weapons. Accountability for these recent attacks has been limited or non-existent, which threatens the credibility of the nonproliferation regime and only encourages further use. Leaders must find the political and moral strength to use a full spectrum of tools to re-establish this system of restraint. This event will discuss ways in which the international community is working to rebuild the system of restraint against chemical weapons, and CSIS will also launch on a report on this topic.”

Clade X Exercise
If you missed out on the live-stream of this table-top exercise hosted by the Johns Hopkins Center for Health Security, don’t worry, you can check out the recording or  awesome live-stream Twitter activity by searching #CladeX. This was a wonderful exercise involving experts like Tara O’Toole, Julie Gerberding, Tom Daschle, etc. Responding to a biological incident, whether intentional, natural, or accidental, is challenging on a good day, but Clade X revealed very serious complications and gaps in our response measures. The Clade X exercise showed real-time decisions and questions that occurred during such an event. From quarantine to MCM and even healthcare worker refusals to work, there were several injects that made this an evolution in infectious disease response across multiple sectors and agencies. Even wild card moments occurred, like Arizona trying to close itself off, which is what made this exercise so engaging and rewarding.

Stories You May Have Missed:

  • Hotel Pools – Icky: it’s something we all knew but didn’t want to admit…hotel pools are pretty dirty. “Today’s report is based on data from the last 15 years said that hotel pools and hot tubs are to blame for one third of waterborne disease outbreaks. The parasite Cryptosporidium and the bacteriaPseudomonas and Legionella cause most outbreaks that begin in swimming venues in the United States. Though chlorine can kill Cryptosporidium, both Pseudomonas and Legionella can survive disinfectants in slimy areas (called biofilm) of hot tubs, pools, and water playgrounds, the CDC said. From 2000 to 2014, public health officials from 46 states and Puerto Rico recorded 27,219 illnesses associated with 493 outbreaks (two or more cases) that originated in treated recreational water. Included in those illnesses were eight deaths.”

Thank you for reading the Pandora Report. If you would like to share any biodefense news, events, or stories, please contact our Editor Saskia Popescu (biodefense@gmu.edu) or via Twitter: @PandoraReport

The Ebola Vaccine and the Ethics of Drug Trials

By Greg Mercer

The World Health Organization recently announced that a trial of the VSV-EBOV Ebola virus vaccine in Guinea has been “highly effective,” and that randomization in the trial would be stopped to allow for expansion of the range of subjects and protection of more people against the virus.  The trial began in March, and until recently, randomized subjects so that some received the vaccine immediately, while others received it later, after the virus’ gestation period.

A paper published in The Lancet details the study, and finds that the vaccine is highly effective and likely safe to use in the affected population.  The “recombinant, replication-competent vesicular stomatitis virus-based” vaccine is administered in a single dose via the deltoid muscle.  4,123 people received the vaccination immediately, while 3,528 people received the delayed vaccination (more on the study methodology in a moment). The researchers found that no subjects developed a case of Ebola after receiving the immediate or delayed vaccination, meaning that the vaccine proved 100% effective (with p=0.0036 at 95% CI).  These findings are excellent news for researchers, government officials, and those in the affected counties, and are fascinating from a scientific standpoint.

At The New Republic, Timothy Lahey, of Dartmouth, argues that these results, while promising, aren’t necessarily confirmed.  He notes that the lack of a placebo (because of the study’s particular methodology) makes it difficult to determine effectiveness, the vaccine could have failed to protect subjects from infection in a way that the study didn’t detect, and that a statistical aberration could mean that while the vaccine is not actually 100 % effective.  Regardless of whether these potential pitfalls affected the study or not, Lahey raises an important issue in drug testing for a disease like Ebola.  He is concerned that a lower standard for vaccines could mean that lower-income countries might not receive drugs of the same quality as rich countries, and points to past failed vaccines to illustrate the fallacy of believing that all vaccines work as intended.

The ethical dilemmas of drug testing have been front and center in the Ebola crisis.  Back in November, 2014, Nature reported on public health officials weighing the question of whether to use control groups when testing treatments for a disease with 70% mortality.  At the time, some advocated for applying experimental treatments (like the ZMapp antiviral cocktail, which had been used in patients but whose effectiveness was not entirely determined) to all patients, while others argued that these treatments might not be more effective than standard care, and that randomized trials guard against harmful side effects and provide a clearer picture of a drug’s effectiveness.

The VSV-EBOV vaccine was tested in the “ring” method that was previously used in the eradication of Smallpox.  This method eschews the double-blind placebo treatments commonly associated with drug trials.  Instead, this method creates a “ring” around new cases.  Contacts and contacts of contacts were identified by Guinea’s tracking system, and eligible adults were entered into randomization blocks, and received either the immediate or delayed vaccination.  This way, all of the subjects received the treatment, but in varying circumstances to establish effectiveness.  The full study is available via The Lancet.

Ethical drug testing is a crucial consideration, and has an imperfect past.  The National Institutes of Health’s own ethics guide cites a study that led to the United States’ ethics rules: a study that withheld syphilis treatment from 400 African-American men.  And for many, there’s good reason to be concerned about the actions of international organizations and multinational corporations.  In 1996, Pfizer conducted a study of an experimental drug on children with meningitis in Nigeria. While Pfizer maintained that the study was philanthropic, allegations arose from Nigerians and international organizations that children and parents were not informed that they were part of a study, and that Pfizer withheld treatment without consent or administered dangerous drugs.  The incident spawned a series of lawsuits and a panel of Nigerian medial experts condemned Pfizer’s actions in 2006, as reported by The Washington Post.

Epidemics and drug testing present a multitude of practical and ethical concerns, but careful consideration of the issues and sound methodology can, as they did in Guinea, produce exciting scientific and humanitarian results.

Image Credit: Psychonaught

Pandora Report 7.26.15

Mason students are working through their summer courses and I’m happy to say mine is OVER! Let the summer begin (two months late)! This week we’ve got great news about Polio in Nigeria and a somber anniversary in Japan. We’ve also got other stories you may have missed.

Enjoy the rest of your weekend and have a great week!

A-Bomb Victims Remembered in Potsdam, Where Truman Ordered Nuclear Strikes

Coming up on the 70th anniversary of the atomic bombs being dropped on Hiroshima and Nagasaki, German and Japanese citizens in the city of Potsdam held a remembrance ceremony for both the victims that died in the blast and the future. Japan has become, according to the former President of the International Court of Justice, the world’s conscience against nuclear weapons and power. Why? Japan is “the only country in the world to have been the victim of both military and civilian nuclear energy, having experienced the crazy danger of the atom, both in its military applications, destruction of life and its beneficial civilian use, which has now turned into a nightmare with the serious incidents of Fukushima.”

Japan Times—“The Potsdam Conference was held between July 17 and Aug. 2 in 1945. The United States dropped an atomic bomb on Hiroshima on Aug. 6 and another bomb on Nagasaki three days later. On Aug. 15 that year, Emperor Hirohito announced to the nation that Japan had accepted the Potsdam Declaration, in which the United States, Britain and China demanded the nation’s unconditional surrender.”

Nigeria Beats Polio

Very, very, very exciting news: Nigeria has not had a case of polio in a year. A year! This makes Nigeria polio free and the last country in Africa to eliminate the disease. The achievement was possible with contributions from the Nigerian government (where elimination of the disease was a point of “national pride”), UNICEF, the WHO, the CDC, the Bill and Melinda Gates Foundation, Rotary International, and other organizations. With Nigeria’s accomplishment, there are only two other countries in the world where polio still exists—Afghanistan and Pakistan.

Voice of America—“Carol Pandek heads Rotary International’s polio program. She told VOA via Skype that a year being polio-free is a milestone for Nigeria, but noted that it is not over. “Now they need to continue to do high quality immunization campaigns for the next several years,” she said, as well as have a strong surveillance system so, should there be any new cases, they can be identified as soon as possible.”

Stories You May Have Missed

 

Image Credit: Fg2

Pandora Report 05.17.15

Yowza! That’s another semester in the books for the GMU Biodefense students. Please excuse the sparse activity on the blog, but with the semester over, things should be getting back to normal.

This weekend we have a updates on Ebola and the bird flu outbreak in the U.S., plus other stories you may have missed.

Have a great week, (enjoy the Mad Men finale!) and see you back here next weekend!

Ebola is (still) living in an American doctor’s eye

As an update, Liberia has (finally) been declared Ebola free, the number of cases in Guinea continue to rise due to transmissions at funerals, and those in Sierra Leone are dying less from Ebola than from other diseases due to the collapse of the healthcare system. It’s been over a year and we are still learning things about Ebola and its persistence on hospital surfaces, sexual fluids, and now, according to a study in the New England Journal of Medicine, the eye. WHO volunteer Ian Crozier was diagnosed in Sierra Leone and transported to Emory University where he was treated. Months later he returned to the hospital with symptoms like blurred vision and acute pain in his left eye. The cause? Ebola.

The Washington Post—“Ebola may have found refuge in patients’ eyes because, researchers said, the eye is walled off from the immune system. As the New York Times put it: “The barriers are not fully understood, but they include tightly packed cells in minute blood vessels that keep out certain cells and molecules, along with unique biological properties that inhibit the immune system.” This phenomenon is called “immune privilege” — and it means the eye can harbor viruses.”

America’s $45 Billion Poultry Industry Has a (Really) Bad Case of Bird Flu

The title says it all, frankly. Since early December 2014 three strains of highly pathogenic avian influenza have been circulating in North America. A state of emergency has been declared in Iowa (one of the hardest hit states) and over 21 million birds have been killed to contain and prevent the spread of the virus. Beyond the culling of birds, the outbreak is having an affect on business—China, South Korea, and Mexico have banned imports of U.S. poultry (to protect their own industries.)

The Motley Fool—“Falling exports could hurt farmers, but it could also help to offset domestic price increases from less supply. Although, with tens of millions of bird deaths and no end in sight to the pandemic, domestic food prices could be the largest casualty in the end.”

Stories You May Have Missed

 

Image Credit: 8thstar

Pandora Report 4.19.15

Sunday has to be the biggest brunch day of the week, so it is only fitting that our lead story looks at the many (delicious and nutritious) uses of maple syrup. We also look at Dengue fever in Brazil, missteps in the U.S. fight against Ebola, and other stories you may have missed.

Once you’re updated, get out there and enjoy the rest of your weekend and the beautiful weather! Have a great week!

Syrup Extract Found to Make Antibiotics More Effective Against Bacteria

It seems like we look at growing antibiotic resistance every week here at Pandora Report. This week, researchers at McGill University in Montreal reported that a “concentrated extract of maple syrup makes disease-causing bacteria more susceptible to antibiotics.” This finding suggests that combining the extract with antibiotics could increase their effectiveness and lead to lower antibiotic usage overall. Honestly, is there anything maple syrup can’t make better?!

Infection Control Today—“‘We would have to do in vivo tests, and eventually clinical trials, before we can say what the effect would be in humans,” [Professor Nathalie] Tufenkji says. “But the findings suggest a potentially simple and effective approach for reducing antibiotic usage. I could see maple syrup extract being incorporated eventually, for example, into the capsules of antibiotics.’”

Brazilian Teams on Alert because of Dengue Fever Outbreak

Brazilian soccer teams are on high alert because of a dengue fever outbreak that has already affected some of the country’s top teams. This week three players were diagnosed with the mosquito borne disease, which normally takes about two weeks to recover from. Players have been forced to use insect repellent during games and practices and health officials have been asked to check fields and training centers for mosquito breeding sites.

USA Today—“Cases of dengue fever have increased significantly across Brazil this year, with most of them reported in Sao Paulo state. Brazil’s health ministry said there have been more than 460,000 cases of the disease in the country in 2015, which accounts for almost 5,000 cases a day. More than 130 people have died so far this year, the ministry said.”

Empty Ebola Clinics in Liberia Are Seen as A Misstep in U.S. Relief Effort

After spending hundreds of millions of dollars and deploying 3,000 U.S. troops to build Ebola treatment centers (E.T.C.) in Liberia, the facilities have largely sat empty. Only 28 Ebola patients have been treated at the 11 E.T.C.s built by the U.S. military. Nine of the centers never had a single Ebola patient. Looking back, the emphasis on building E.T.C.s had far less of an impact than the “inexpensive, nimble measures taken by residents to halt the outbreak.”

The New York Times—“Had the Americans and other donors been more flexible, critics and some officials contend, the money could have been put toward rebuilding Liberia’s shattered health care system—or backing the efforts of local communities—instead of focusing on treatment centers that would scarcely be used.”

Stories You May Have Missed

 

Image Credit: Dvortygirl

Pandora Report 2.15.15

It’s the last holiday weekend before the summer and its too cold to go outside! Don’t worry, we’ve got some good reading while you’re staying warm inside: antibiotic resistance, U.S. Troops leaving West Africa, a new vaccine for polio and LOTS of stories you may have missed.

Enjoy your Monday holiday and have a safe and healthy week!

Rivers Can Be a Source of Antibiotic Resistance

As the U.S. Government increases its funding to fight growing antibiotic resistance, a study coming out of the University of Warwick’s School for Life Sciences and the University of Exeter Medical School points to rivers and streams as a major source of antibiotic resistance in the environment. The study of the Thames River found that greater numbers of resistant bacteria existed close to some wastewater treatment plants and that these plants are likely “to be responsible for at least half of the increase observed.”

R&D Magazine—“The team also found that several other factors affected the prevalence of antibiotic resistance, such as changes in rainfall and land cover. For example, heavy rainfall at a point surrounded by grassland raised resistance levels; whereas a heavy rainfall at a point surrounded by woodland reduced the levels seen.”

U.S. Bringing Home Almost All Troops Sent to Africa in Ebola Crisis

The U.S. military is bringing home nearly all troops that were sent to West Africa 10 months ago in order to fight the Ebola outbreak. This withdrawal comes at a time where 700 homes in Sierra Leone were put under quarantine after a new case was diagnosed in Freetown. Quarantine seems like a smart move, since researchers have now confirmed that the virus can remain contagious on a dead body for up to a week. Despite troops leaving, testing has begun in Liberia for two potential vaccine candidates.

CNN—“[Pentagon press secretary Rear Adm. John] Kirby said about 100 military service members will remain in West Africa to support the 10,000 civilian responders who remain. These service members will “build on a strong military partnership with the Armed Forces of Liberia to enhance their Ebola response efforts and provide disaster response training to the government of Liberia,” he said.”

Synthetic Vaccine Sought to Finally Eradicate Polio

While, after six months of no new cases, Africa is close to wiping out wild polio, a team of international scientists are working to create a wholly artificial vaccine to combat the disease. The Bill and Melinda Gates Foundation and the World Health Organization are providing a $647,000 grant to create an entirely synthetic approach that will address shortcomings in the existing vaccine. This new vaccine would be entirely virus free.

BBC—“…the existing oral vaccine uses a weakened version of the virus as its stimulus to provoke a response and protection in the patient. And in just a few particular individuals, this can set up an infection in the gut that then enables a reactivated virus to pass out of the body and spread to other, unvaccinated people.

But if the virus particle has no genetic machinery this transmission route is closed, and the World Health Organization and the Gates Foundation is to fund the scientists to engineer just such particle for use as a replacement vaccine.”

Stories You May Have Missed

  

Image Credit: Wikimedia Commons

Pandora Report 2.1.15

No themed coverage this week, sadly. However, we’ve got stories covering the Federal fight against antibiotic resistance, ISIS airstrikes, and super mosquitoes in Florida. All this in addition to stories you may have missed.

Have a fun Super Bowl Sunday (go team!) and a safe and healthy week!

Obama Asking Congress to Nearly Double Funding to Fight Antibiotic Resistance to $1.2 Billion

One of The White House’s goals for 2015 was to combat growing antibiotic resistance through research into new antibiotics and efforts to prevent the over prescription of these vital drugs. President Obama is requesting that Congress add additional funding to this fight, bringing the total to $1.2 billion. The funding will be a start, but there are many other things that can happen in order to fight this extremely important problem.

U.S. News & World Report—“The Centers for Disease Control and Prevention says more than 23,000 Americans die every year from infections that can withstand some of the best antibiotics. The World Health Organization said last year that bacteria resistant to antibiotics have spread to every part of the world and might lead to a future where minor infections could kill.”

Air Strike Kills IS ‘Chemical Weapons Expert’

News came Saturday morning that U.S. airstrikes in Iraq last week killed a mid-level Islamic State militant who specialized in chemical weapons. Killed on January 24, Abu Malik had worked at Saddam Hussein’s Muthana chemical weapons production facility before joining Al-Qaeda in Iraq in 2005.

Radio Free Europe/Radio Liberty—“Officials say his death could “temporarily degrade” the group’s ability to produce and use chemical weapons. Coalition air strikes have pounded the Mosul area over the past week [and] The U.S.-led coalition has carried out more than 2,000 air raids against IS militants in Syria and Iraq since August 8.”

Millions of Genetically Modified Mosquitoes Could Fight Disease in Florida

On January 11, we had a small note about the possibility of genetically modified mosquitos controlling diseases like chikungunya and dengue, but this week coverage on this issue absolutely exploded! British biotech firm Oxitec plans to release millions of genetically modified mosquitos in Florida to control the existing population and help control the spread of these diseases. The A. Aegypti species of mosquito is extremely prevalent in Florida and recently has become resistant to most chemical pesticides. Residents, of course, are up in arms over the potential release of this “mutant mosquito”.

The Weather Channel—“Technology similar to this is already in use in Florida and other states, Entomology Today points out. Sterile Insect Technique (SIT) employs a similar technique, sterilizing insects so that when they mate, no offspring are produced. “Florida spends roughly $6 million a year using SIT to prevent Mediterranean fruit fly infestations, while California spends about $17 million a year,” Entomology Today wrote.”

Stories You May Have Missed

Image Credit: Wikimedia Commons

Pandora Report 1.18.15

For those who’ve been reading for awhile, you’ve probably surmised that one of my personal health interests is seasonal and pandemic flu. There were plenty of stories about that this week, so that’s what we’ll focus on. We’ll also look at Ebola and other stories you may have missed. My apologies for posting delays this week, I’m dealing with some rotator cuff and carpal tunnel issues in my right arm, and let me tell you, it is HARD to type with your dominant arm in a sling!

Enjoy your holiday Monday (if you have one) and have a safe and healthy week!

Texas Health Experts Say Universal Flu Vaccine Could be a Reality

The CDC has said that this year’s seasonal flu vaccine was only 23% effective due to unanticipated antigenic drift—meaning the predicted strains in the vaccine didn’t match the dominant strains of the virus that are currently circulating. In order to combat this in the future, scientists at Mount Sinai health system in New York are in the process of testing a universal flu vaccine which will go into clinical trials this year.

KLTV.com—“‘There is work going on to see if, perhaps a different kind of vaccine could be developed maybe against a different part of the flu virus, one that is not so subject to this antigenic drift or to change as readily from one year to the next,” [Dr. Levin of UT Health Northeast] says.”

Scientists Find Brain Protein Aids Influenza Recovery

Scientists at Washington State University in Spokane have found a brain protein that boosts the healing power of sleep and speeds recovery from the flu in mice. Professor James M. Kruger said this discovery could lead to alternative treatments for flu and other infectious diseases by stimulating production of the brain protein called AcPb. This discovery comes at a time where avian influenza is prevalent in Taiwan, Japan, Nigeria, China, Egypt, Canada, the U.S. and Mexico.

Washington State University—“Krueger showed this recovery involves AcPb and an immune system signaling chemical called interleukin-1. AcPb links up with interleukin-1 to help regulate sleep in healthy animals. It also prompts infected animals to spend more time sleeping during an illness.

In the study, mice who lacked the gene for AcPb slept less after being infected with influenza virus. They also became chilled, grew sluggish, lost their normal circadian rhythms and ultimately died in higher numbers than the mice who slept longer.”

This Week in Ebola

As GMU students return to classes, so do students in Ebola affected Guinea. Schools in Guinea will re-open Monday, and schools in Liberia are set to re-open “next month.” No date has been set for schools in Sierra Leone. Despite this, the President of Sierra Leone has declared that there will be zero new confirmed Ebola cases by the end of March the country will be Ebola-free, by WHO standards, by May. These announcements come at a time when Dr. Thomas Frieden, Director of the CDC, has said he was “very confident we can get to zero cases in this epidemic if we continue the way we’re going and nothing unexpected happens” and the outbreak appears to be slowing down. Last week brought record low numbers—for Guinea, the lowest total since mid-August; for Liberia, the lowest total since the first week of June; for Sierra Leone the second week of declines and the lowest level since the end of August. However, there are still “at least 50 micro-outbreaks” underway throughout West Africa.

Pauline Cafferkey, the Scottish nurse infected with Ebola, is “showing signs of improvement” and an American soldier who was found dead in Texas after his deployment in West Africa reportedly showed no signs of Ebola leaving officials to remark that there was “no evidence of a public health threat.”

A seemingly large amount of good news this week left space for new ruminations on Ebola and outbreaks in general. Wired  had an interesting piece on Nanobiophysics and how it could stop future global pandemics while The Chicago Tribune looked at bats and their likely role in Ebola outbreaks and CNBC looked at the price of protection from global pandemics—would you believe $343.7 billion?

Stories You May Have Missed

 

Image Credit: NBC News